PF-CBP1 NEW
| Price | $29 | $38 | $66 |
| Package | 2mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: PF-CBP1 | CAS No.: 1962928-21-7 |
| Purity: 99.91% | Supply Ability: 10g |
| Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | PF-CBP1 |
| Description | PF-CBP1 HCl is a highly selective inhibitor of the bromodomain of CREB-binding protein(CREBBP). It inhibits CREBBP (IC50: 125 nM) and p300 bromodomains (IC50: 363 nM). |
| Cell Research | Cells are pretreated with the probes PF-CBP1, ISOX-INACT, or ISOX-DUAL starting at 10 μM concentrations, and then serially diluted to 0.1 μM. After 30 min, the cells are treated with LPS to induce gene transcription and the expression levels of interleukin-6 (IL-6), IL-1β, and interferon-β (IFN-β)(which are known to be induced after 4 h of LPS exposure) are analyzed by RT-PCR. Probe PF-CBP1 moderately reduces LPS-induced IL-6 and IFN-β expression at 10 μM, and a decrease in IL-1β expression is evident at 3 μM. (Only for Reference) |
| In vitro | PF-CBP1 modulates key inflammatory genes in primary macrophages, downregulates RGS4 in neurons (a target linked to Parkinson's disease), and exhibits 139-fold selectivity over BRD4 in biochemical assays and >105-fold selectivity by ITC. PF-CBP1 is a potent EP300 inhibitor with no cytotoxicity in macrophages and no hepatotoxicity in cell-based models at non-toxic concentrations. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 50 mg/mL (102.33 mM) |
| Keywords | PFCBP1 | PF-CBP-1 | Inhibitor | Epigenetic Reader Domain | PF CBP1 | PF-CBP1 | inhibit |
| Inhibitors Related | ABBV-744 | CeMMEC1 | 3-methyl-1,2,3,4-tetrahydroquinazolin-2-one | (+)-JQ-1 | J-147 | Anacardic Acid | Curcumin | dBET6 | Piflufolastat | Naphthol AS-E | Bisdemethoxycurcumin | GSK1379725A |
| Related Compound Libraries | Highly Selective Inhibitor Library | Histone Modification Compound Library | Bioactive Compound Library | Epigenetics Compound Library | Inhibitor Library | NO PAINS Compound Library | PPI Inhibitor Library | Bioactive Compounds Library Max |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $0.00/10g |
VIP3Y
|
HangZhou RunYan Pharma Technology Co.,LTD.
|
2024-09-20 | |
| $0.00/1G |
VIP4Y
|
Wuhan Nutra Biotechnology Co.,Ltd
|
2022-05-28 | |
| $0.00/1gram |
VIP3Y
|
Wuhan Senwayer Century Chemical Co.,Ltd
|
2022-12-08 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY